

# IVI's 20<sup>th</sup> International Vaccinology Course Agenda



September 06-10 2021

Korea Standard Time (PM)

<b>SEPT 06 MON DAY 1</b>		<b>Opening &amp; Role of International Organizations in the COVID-19 Pandemic Response</b>	Moderator : Anh Wartel, DDG of CARE unit, IVI
<b>Opening Session</b>			
3:00-3:05	0-1	Opening Remarks	Anh Wartel, Course Director, IVI
3:05-3:10	0-2	Congratulatory Remarks	Kim Jung-sook First Lady of the Republic of Korea Honorary President, Korea Support Committee for IVI
3:10-3:25	0-3	Keynote Speech	Jerome Kim, Director General, IVI
<b>Role of International Organizations in the COVID-19 Pandemic Response</b>			
3:25-4:05	1-1	SARS-Cov2 Variants Of Concern Update	Sylvie Briand, WHO
4:05-4:25	1-2	Global Supply Of COVID-19 Vaccines - COVAX Facility	Derrick Sim, Gavi
4:25-4:50	1-3	Vaccine Diplomacy in a Time of Anti-Science	Peter J. Hotez, Baylor University
4:50-5:15	1-4	COVID-19 Different Vaccine Platforms Development	Jakob Cramer, CEPI
5:15-5:45	1-5	Lessons Learned Of Vaccine Roll-Out In Canada	Beate Sander, UHN Research
5:45-6:05	1-6	Opportunity For Developing Country Vaccine Manufacturing Capacity	Sai D. Prasad, Bharat Biotech/DCVMN President
6:05-6:30	1-7	Is COVID-19 Eradication Possible?	Youngmee Jee, Institut Pasteur Korea
<b>SEPT 07 TUE DAY 2</b>		<b>Immunology of COVID-19</b>	Moderator : Manki Song, DDG of Science unit, IVI
3:00-3:25	2-1	Basic Immunology-What do Vaccinologists Need to Know?	Hazel Dockrell, LSHTM
3:25-4:00	2-2	Immunology : Wild-Type Infection, Re-Infection, and Herd Immunity	Nakorn Prem Sri, National Vaccine Institute, Thailand
4:00-4:25	2-3	Correlates of Vaccine-induced Immunity	Stanley Plotkin, University of Pennsylvania
4:25-4:51	2-4	Structure-based Vaccine Design	Peter D. Kwong, Vaccine Research Center, US NIH
<b>SEPT 08 WED DAY 3</b>		<b>Pre-clinical Studies and Vaccine Development for COVID-19</b>	Moderator : Ravi Ganapathy, Head of Vaccine Development, IVI
3:00-3:25	3-1	Overview Of Vaccine Development & Manufacturing	Ravi Ganapathy, IVI
3:25-3:50	3-2	COVID-19 Vaccines And Adjuvants	Nikolai Petrovsky, Flinders University
3:50-4:15	3-3	Vector-based COVID-19 Vaccine	Hanneke Schuitemaker, Janssen Vaccines & Prevention B.V.
4:15-4:45	3-4	Laboratory Assessment of Vaccines	Mark Page, NIBSC
4:45-5:12	3-5	Vaccine Development in Non-human Primate Model	Neil Berry, NIBSC
<b>SEPT 09 THUR DAY 4</b>		<b>Clinical Development, Clinical Data, Knowledge gaps</b>	Moderator : Sushant Sahastrabudhe, Associate Director General, IVI
3:00-3:27	4-1	Vaccine Clinical Development	Zenaida Reynoso Mojares, IVI
3:27-3:52	4-2	Statistical Methods for Vaccine Development	DeokRyun Kim, IVI
3:52-4:23	4-3	Maternal Immunization	Flor Munoz, Baylor University
4:23-4:57	4-4	Post Marketing Vaccine Safety Pharmacovigilance	Jean-Louis Excler, IVI
4:57-5:25	4-5	Vaccine Communication and Vaccine Hesitancy	Pauline Paterson, LSHTM
<b>SEPT 10 FRI DAY 5</b>		<b>AMR, Epidemiology and Health Economics</b>	Moderator : Birkneh Tilahun Tadesse, Research Scientist, IVI
3:00-3:25	5-1	Role of Vaccines in Reducing AMR	Elizabeth Klemm, Wellcome Trust
3:25-3:55	5-2	Whole Genome Sequencing in AMR	Iruka Okeke, University of Ibadan
3:55-4:22	5-3	Evaluating Vaccine Protection in Clinical Trials : Efficacy versus Effectiveness	John D. Clemens, IVI
4:22-4:47	5-4	Role of Health Economics and Financing in New Vaccine Introduction	Mark Jit, LSHTM
4:47-5:14	5-5	Introduction to Disease Transmission Modeling	JongHoon Kim, IVI
5:14-5:19	5-6	Closing Remarks	Jerome Kim, Director General, IVI

Sponsored by :

